• Home
  • About Us
    • About Us
    • Leadership Team
  • Science
    • Biologics
    • Biomanufacturing
    • Pipeline
  • Investors
    • Overview
    • SEC Filings
    • Press Releases
    • Presentations
    • Corporate Governance
    • Investor Resources
      semaglutide
      • Email Alerts
      • FAQs
      • Tax Documents
  • Careers
  • Contact Us

Tivic Health Announces New Bioelectronic Sinus Pain Benefits At CES Eureka Park 50527

Dec 30, 2019 | Press Releases

CEO, Jennifer Ernst, Speaking On Bioelectronic Medicine At CES Digital Health SummitSAN FRANCISCO, Dec. 30, 2019 — Tivic Health™ Systems Inc., a CES 2020 Innovation Award Honoree, will be at CES in Eureka Park booth 50527 demonstrating ClearUP® Sinus...

Tivic Health Announces New Bioelectronic Sinus Pain Benefits At CES Eureka Park 50527

Dec 30, 2019 | Press Releases

CEO, Jennifer Ernst, Speaking On Bioelectronic Medicine At CES Digital Health SummitSAN FRANCISCO, Dec. 30, 2019 — Tivic Health™ Systems Inc., a CES 2020 Innovation Award Honoree, will be at CES in Eureka Park booth 50527 demonstrating ClearUP® Sinus...
Next Entries »

Recent Posts

  • Valion Bio Welcomes Former U.S. Army Regulatory Leader and Biotech CEO Dr. Armand Balboni as Advisor in Run-up to Entolimod Therapeutic Efficacy Data Readout
  • Valion Bio Reports Completion of 200-Liter Entolimod Production Run; Material Supplying Ongoing AFRRI Study
  • Valion Bio Reinforces Commitment to American Troops; Discusses Entolimod with Attendees at RW Baird’s National Security Conference
  • Valion Bio Advancing Entolimod into U.S. Government-Funded Therapeutic Efficacy Study Following Positive Safety Results
  • Valion Bio Announces Positive Safety Results From U.S. Government-Funded Entolimod Study, Paving Way For Therapeutic Efficacy Evaluation

Recent Comments

No comments to show.
©2026 Valion Bio

Privacy Policy

For ClearUP customer questions regarding warranty or other device inquiries, please reach out to customerservice@tivichealth.com.